Company Overview of Targazyme, Inc.
Targazyme, Inc., a biotechnology company, develops and commercializes products in the fields of cell and immunotherapy. The company’s products include TZ101 that attaches the sugar fructose to therapeutic cells, such as stem cells or immune cells to increase the ability of those cells to attach to selectins, which are proteins that are up regulated under conditions of inflammation, ischemia, and tissue damage. Its TZ101 is used for various applications for patients with cancer, such as cord blood transplantation for hematological malignancies, regulatory T cells and mesenchymal stem cells for graft versus host diseases, and natural killer cells for multiple myeloma and leukemia; Ischemic dis...
3200 County Road 104
Floresville, TX 78114
Founded in 2005
Key Executives for Targazyme, Inc.
Co-Founder and Vice President of Manufacturing
Co-Founder and Vice President of Research
Associate Chief Medical Officer
Senior Vice President of Regulatory Affairs & Quality Assurance
Compensation as of Fiscal Year 2014.
Targazyme, Inc. Key Developments
TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board
Jun 3 14
TargaZyme, Inc. announced that it has appointed Christopher Calhoun to its Business Advisory Board. Chris Calhoun is a co-founder of Cytori Therapeutics. He has served as its Vice-Chairman/Director and Chief Executive Officer.
Targazyme, Inc. Appoints Mark W. Schwartz to Board of Directors
Mar 4 14
Targazyme, Inc. (formerly America Stem Cell, Inc.) announced that it has appointed Mark W. Schwartz, Ph.D. to the company's Board of Directors. Dr. Schwartz will serve the company as an independent member of the Board. As an independent director, Dr. Schwartz will assist in the company in further enhancing its corporate governance protocols and oversight committees, as well as assist management in setting and meeting corporate goals, including establishing key strategic partnerships and providing guidance on long-term capital raising in both private and public markets. With the appointment of Dr. Schwartz as the company's fourth Board member and third independent director, the company has achieved Sarbanes-Oxley compliance with respect to Board composition.
Targazyme, Inc. Presents at 16th Annual BIO CEO & Investor Conference 2014, Feb-10-2014 11:30 AM
Feb 7 14
Targazyme, Inc. Presents at 16th Annual BIO CEO & Investor Conference 2014, Feb-10-2014 11:30 AM. Venue: The Waldorf-Astoria Hotel, Conrad Room, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|